Patient Perspectives in Mantle Cell Lymphoma Clinical Research

NCT06049472 · tracked via the Priya Life Science USA tracker

Sponsor

Power Life Sciences Inc.

Phase

Observational

Started

2024-10

Last updated

2023-09-22

Condition(s) studied

Mantle Cell Lymphoma

Study summary

Clinical studies with a distinct emphasis on mantle cell lymphoma play a pivotal role in evaluating the safety and effectiveness of novel treatments for this disease. These trials are instrumental in ascertaining whether new medications surpass conventional therapies, providing substantial evidence to endorse their broad utilization.

This particular study stands out as it centers on the firsthand experiences of individuals battling mantle cell lymphoma who are actively engaged in a clinical trial featuring medicinal interventions. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this patient group.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Confirmed diagnosis of mantle cell lymphoma * No serious medical or psychiatric illness likely to interfere with participation in this clinical study. * Ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Concurrent participation in another therapeutic clinical trial. * Subject has an uncontrolled infection * Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial

Primary outcome measure(s)

Number of patients who decide to enroll in a mantle cell lymphoma clinical study — 3 months
Rate of patients who remain in a mantle cell lymphoma clinical study to trial completion — 12 months

Trial sites (1)

Facility	City	Region	Status
Power Life Sciences	San Francisco	California

More Power Life Sciences Inc. trials in the USA

Investigating Engagement Patterns and Participation Trends Among Liposarcoma Patients Starting soon

A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study Starting soon

Examining Engagement Trends Among Participants in Peripheral Neuropathy Clinical Research Starting soon

Revealing Engagement Dynamics Among Semantic Dementia Patients Starting soon

Revealing Engagement Dynamics Among Diabetic Kidney Disease Patients Starting soon

Other trials for the same condition

Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies Active, not recruiting

A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers. Recruiting

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006) Active, not recruiting

Study of BGB-11417 Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma Active, not recruiting

A Long-term Extension Study of PCI-32765 (Ibrutinib) Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06049472 on ClinicalTrials.gov ↗ ← All trials in the USA